Home › NDC Lookup › Ingredients › Aprepitant › 68462-0583-85
💊image loading
(from DailyMed)

Aprepitant 40 mg Capsule, 5-count — NDC 68462-583-85 (Billing 68462-0583-85)

by Glenmark Pharmaceuticals Inc., USA · 5 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK

This is a package of 5 capsules of Aprepitant 40 mg Capsule from Glenmark Pharmaceuticals Inc., USA, marketed since Oct 2017 and currently FDA-listed; retail pharmacies pay about $46.42 per capsule (NADAC).

NDC 68462-0583-85
🏷️ FDA NDC (as labeled) 68462-583-85 billing pads the product segment with a zero
This package
Contains5-count Cost per ea$46.42 NADAC Per package$232.10 / 5 capsule Pack sizes3 compare ↓
Also priced by: Medicaid pays $105.84/unit · Part D plans $191.47/unit — full pricing hub ↓
Product page 68462-0583-40 Also comes in: 1 capsule 68462-583-40 10 capsules 68462-583-11
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 68462-583-85 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
68462 labeler · 583 product · 85 package
Package marketed since
Oct 12, 2017
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
5 EA per package
Barcode (UPC-A, from the NDC)
3 6846258385 2
Medicaid fills, this package
1,672 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Aprepitant (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Dec 12, 2025 — Presence of particulate matter: potential presence of metal particulates in the product. (Merck Sharp & Dohme LLC) · FDA recall D-0241-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 68462-583-85
Product NDC 68462-583
11-digit billing NDC 68462058385
NCPDP billing unit EA — each (per item)
Application # ANDA207777
SPL Set ID 39fda225-0fa7-41d3-85b1-6ea966847331
Established class (EPC) Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of action Cytochrome P450 2C9 Inducers; Cytochrome P450 3A4 Inducers; Cytochrome P450 3A4 Inhibitors; Neurokinin 1 Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-10-12
Route ORAL
Dosage form CAPSULE
Substance APREPITANT
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 061115
GCN 27278
HICL code 025058
Ingredient (HICL) Aprepitant
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6J
Therapeutic class — specific (HIC3) Antiemetic/Antivertigo Agents
AHFS code 56:22.32.00
AHFS class Neurokinin-1 Receptor Antagonists
FDB label name APREPITANT 40 MG CAPSULE
FDB brand name Aprepitant
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 061115
  • GCN: 27278
  • HICL (First Databank): 025058
  • AHFS class code: 56:22.32.00
Why two NDCs? The FDA registers this code as 68462-583-85 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68462-0583-85. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name APREPITANT 40 MG CAPSULE Ingredient Aprepitant
📗 Our plain-language guide HelloPharmacist
  • It helps prevent nausea and vomiting. Depending on the product, that means nausea from chemotherapy (taken with other anti-nausea medicines) or nausea after surgery. It is not mean...
  • Capsules are swallowed whole, with or without food. For chemotherapy, you usually take them about an hour before treatment over about three days. For surgery, one dose is taken bef...
  • Common ones include tiredness, diarrhea, indigestion, stomach pain and hiccups. After surgery, constipation and low blood pressure can happen. Call your doctor right away for hives...
  • It can. Hormonal birth control may work less well while you take aprepitant and for 1 month after your last dose. Use a back-up method like condoms during that time.
📖 Read our full Aprepitant guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $46.421 $232.10 / 5 capsule
Medicaid paysCMS SDUD · 12 mo $105.84 $529.22 / 5 capsule
Medicare drug plans payPart D · Q2 2026 $191.47 $957.36 / 5 capsule
Medicare Part B allowsASP · J8501 $3.069 / J8501 unit —
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Oct 2022 Feb 2026 Sep 2026 $74.054 $38.186
▼ Down 30% over the last 22 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)68462-583-85
11-digit billing NDC68462-0583-85
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ8501
DescriptorAPREPITANT, ORAL, 5 MG
Billing units / pkg8 units
How the units are derivedThis package is 5 EA; the HCPCS unit is 5 MG, so one package = 8 billing units.
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
68462-0583-11 68462-583-11 1 BLISTER PACK in 1 CARTON / 10 CAPSULE in 1 BLISTER PACK — — 2017-10-12 — Active
68462-0583-40 68462-583-40 Main listing 1 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK $46.42 / ea $46.42 2017-10-12 — Active
68462-0583-85 You're viewing this 5 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK $46.42 / ea $232.10 2017-10-12 — Active

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($46.42 NADAC).

This pack accounts for about 28% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 5-count package — 5 blister pack in 1 carton / 1 capsule in 1 blister pack.
How does this package differ from NDC 68462-0583-40?
Both are Aprepitant 40 mg Capsule — the drug itself is identical. This page's package is the 5-count one, while NDC 68462-0583-40 is the 1 capsule package.
What NDC number is used to bill for this package of Aprepitant 40 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Aprepitant 40 mg 00781-2321-06 Sandoz 1 capsule $46.421 AB Availability likely —
Aprepitant 40 mg 13668-0591-81 Torrent 1 capsule $46.421 AB Availability likely —
Aprepitant 40 mg 68001-0666-01 BluePoint 1 capsule $46.421 AB Availability likely —
Aprepitant 40 mgthis 68462-0583-85 Glenmark 5 capsules $46.421 AB Availability likely —
Aprepitant 40 mg 51407-0701-01 Golden 1 capsule — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Oct 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Aprepitant inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerGlenmark Pharmaceuticals Inc., USA
Application holderGLENMARK SPECIALTY SA
FDA applicationANDA207777 (ANDA)
Labeler code68462
First marketedOct 2017
Product typeHuman Prescription Drug
Portfolio343 products on file

More NDCs from Glenmark Pharmaceuticals Inc., USA labeler code 68462

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.7K
Units reimbursed last 4 qtrs
6.2K
Gross reimbursed last 4 qtrs
$654.4K
Avg / prescription
$391.41
Avg / unit
$105.85
Latest quarter Q4 2025
225Rx
Medicaid pays / ea
$105.85
gross reimbursed
vs
NADAC / ea
$46.4206
acquisition cost
=
Spread
+$59.4297
+128% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
16% FFS 84% MCO
Fee-for-service · 268 Rx Managed care · 1,404 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 691 units · 11.7 per 100k residents WI Michigan: 38 units · 0.4 per 100k residents MI New York: 101 units · 0.5 per 100k residents NY Vermont: no data reported VT New Hampshire: 18 units · 1.3 per 100k residents NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 3,700 units · 31.4 per 100k residents OH Pennsylvania: 243 units · 1.9 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 464 units · 1.2 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 132 units · 6.2 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 741 units · 6.8 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 55 units · 0.2 per 100k residents FL
Units reimbursed · per 100k residents
0.231.4
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Ohio 31.4 /100k
2 Wisconsin 11.7 /100k
3 North Carolina 6.8 /100k
4 New Mexico 6.2 /100k
5 Pennsylvania 1.9 /100k
6 New Hampshire 1.3 /100k
7 California 1.2 /100k
8 New York 0.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 capsule68462-0583-40 4,336 Rx · $712,816
1 capsule this page68462-0583-85 1,672 Rx · $654,438
10 capsules68462-0583-11 No Medicaid data
Drug total (last 4 qtrs): 6,008 Rx · 15,272 units · $1,367,254 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Aprepitant — the program that covers self-administered drugs. 4 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Aprepitant. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.62M
Claims incl. refills
3K
Beneficiaries
1.8K
Spend / beneficiary
$1,460.29
Spend / claim
$873.74
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 68462-0582-01 · Glenmark 68462-0584-58 · Glenmark →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.